(BW) (BIOMED-COMM-INC) U.S. Patent allowance awarded to new alternative medicine new technology; includes cost-efficient AIDS medicines Business Wire
click here to return to Business Wire main menu
DonateNow





(BW) (BIOMED-COMM-INC) U.S. Patent allowance awarded to new alternative medicine new technology; includes cost-efficient AIDS medicines

BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Friday, 13 December 1996.


SEATTLE--(BUSINESS WIRE)--Dec. 13, 1996--U.S. Patent Notice of Allowance on a new alternative medicine was awarded to Biomed Comm Inc., Seattle.

It is the first company to patent homeopathic growth factors for use as an alternative medicine, developed by Dr. Barbara Brewitt, Biomed chief scientific officer.

In 1995, Brewitt's clinical study of a combination of four homeopathic growth factors on HIV-positive individuals successfully demonstrated positive, statistically significant outcomes. The double-blind placebo study was conducted with the assistance of the University of Washington and Bastyr University, Seattle.

Thirty HIV/AIDS patients using the combination of four homeopathic growth factors experienced: a decrease in HIV viral infection; CD4 cell counts that increased over time; weight gain of an average of 10 pounds; less general inflammation and infection; improved immune function; an absence of opportunistic infections; and improved mineral status in the blood.

The results of the clinical studies have been recognized by the National Institutes of Health (NIH) Office of Alternative Medicine (OAM) with a technical merit, number one rating for alternative approaches to HIV/AIDS.

The proposed cost of the new, over-the-counter therapy of the four homeopathic growth factors is $1,440 per year.

"The concept of homeopathic growth factors represents a major breakthrough in reduction of health care costs, for healthy and chronically ill individuals," Brewitt said. "For reasons that homeopathic medicines are highly diluted, cost reductions by 80 to 90 percent over conventional medicines are hoped to offer effective preventive options."

Growth factors represent a specific class of proteins produced by the human body, and regulate cell growth, division, and specialization. They enable cells to communicate with one another, and are termed by Biomed as Cell Signal Enhancers, CSEs.

"These homeopathic growth factors represent a new class of medicines, combining today's advanced biotechnologies, modern molecular biology, and basic homeopathic principles formed two centuries ago," Brewitt added.

Homeopathy is a form of natural medicine, which uses immeasurably small concentrations of medicines to stimulate the human body's own defense and healing processes. It uses natural substances to maintain and enhance immune, nervous, and hormonal systems.

Biomed Comm Inc. was formed in May 1996 upon the premise that the integration of biotechnology advances in genetically engineered growth factors and homeopathic manufacturing make possible the development of a new class of medicine that would produce a wide variety of valuable products for health care and the promotion of wellness in healthy individuals, and used by chronically ill patients that have not found relief from conventional medicines, or who seek complementary supplements to augment their prescription drugs.

The company now is taking orders for the delivery of homeopathic growth factors in January 1997.

--30--CB/np*

CONTACT: Biomed Comm Inc., Seattle Dr. Barbara Brewitt/C. Michael Varner 206/284-3433 or Conaway & Associates Steve Shattuck 714/744-4551 URL: http://biomedcomm.com

REPEATS: New York 212-752-9600 or 800-221-2462; Boston 617-236-4266 or 800-225-2030; SF 415-986-4422 or 800-227-0845; LA 310-820-9473 Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: http://www.businesswire.com


Keywords: CALIFORNIA WASHINGTON MEDICINE PRODUCT

Copyright (c) 1996/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.KWDcaliforniawashingtonmedicineproduct
961213
961212


Copyright © 1996 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .